Blog

In the competitive arena of drug development, the Investigational New Drug (IND) filing represents the first major regulatory hurdle on the path to clinical trials.

In the rapidly evolving landscape of biopharmaceutical manufacturing, the transition from laboratory discovery to commercial-scale production remains one of the most significant hurdles for drug